Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 338Neoplasms, Plasma Cell 56Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Recurrence 50Lymphoma 48Leukemia 39Neoplasms 27Lymphoma, Mantle-Cell 27Burkitt Lymphoma 26Lymphoma, Large B-Cell, Diffuse 23Immunoglobulin Light-chain Amyloidosis 23Lymphoma, Non-Hodgkin 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 17Leukemia, Lymphocytic, Chronic, B-Cell 16Hodgkin Disease 14Nausea 12Lymphoma, Extranodal NK-T-Cell 12Lymphoma, B-Cell, Marginal Zone 12Vomiting 11Smoldering Multiple Myeloma 11Prostatic Neoplasms 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Breast Neoplasms 11Renal Insufficiency 10Neoplasm Metastasis 9Lymphoma, Large-Cell, Immunoblastic 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 8Leukemia, Biphenotypic, Acute 7

Interventions

XENP 1595 2Dexamethasone 2pomalidomide 1fasudil 1birtamimab 1Melphalan 1Calcium Dobesilate 1Bortezomib 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Alzheimer Disease × Dexamethasone × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT01083316 2020-09-25

Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

Boston Medical Center

Phase 2 Completed
35 enrolled 9 charts
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡